Evidence map›Paper›PMID 37733137›Full record

ReviewHeart failure reviews2024

Stem cell-based therapies for heart failure management: a narrative review of current evidence and future perspectives.

Gbolahan Olatunji, Emmanuel Kokori, Ismaila Yusuf, Emmanuel Ayanleke, Olakanmi Damilare, Samson Afolabi, Busayo Adetunji, Saad Mohammed, Olumide Akinmoju, Gbolahan Aboderin and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Heart failure reviews, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Observational
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Gbolahan OlatunjiDepartment of Medicine and Surgery, University of Ilorin, Ilorin, Nigeria.
Emmanuel KokoriDepartment of Medicine and Surgery, University of Ilorin, Ilorin, Nigeria.
Ismaila YusufDepartment of Medicine and Surgery, Obafemi Awolowo University, Osun, Nigeria.
Emmanuel AyanlekeDepartment of Medicine and Surgery, University of Ilorin, Ilorin, Nigeria.
Olakanmi DamilareDepartment of Medicine and Surgery, Ladoke Akintola University Teaching Hospital, Ogbomoso, Nigeria.
Samson AfolabiDepartment of Medicine and Surgery, Ladoke Akintola University Teaching Hospital, Ogbomoso, Nigeria.
Busayo AdetunjiDepartment of Medicine and Surgery, Ladoke Akintola University Teaching Hospital, Ogbomoso, Nigeria.
Saad MohammedAl-Kindy College of Medicine, University of Baghdad, Baghdad, Iraq.
Olumide AkinmojuCollege of Medicine, University of Ibadan, Ibadan, Nigeria.
Gbolahan AboderinDepartment of Medicine and Surgery, Ladoke Akintola University Teaching Hospital, Ogbomoso, Nigeria.
Nicholas AderintoDepartment of Medicine and Surgery, Ladoke Akintola University Teaching Hospital, Ogbomoso, Nigeria. Nicholasoluwaseyi6@gmail.com.
Ladoke Akintola University of Technology · NGUniversity of Ilorin · NGObafemi Awolowo University · NGUniversity of Baghdad · IQUniversity of Ibadan · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure (HF) is a prevalent and debilitating global cardiovascular condition affecting around 64 million individuals, placing significant strain on healthcare systems and diminishing patients' quality of life. The escalating prevalence of HF underscores the urgent need for innovative therapeutic approaches that target the root causes and aim to restore normal cardiac function. Stem cell-based therapies have emerged as promising candidates, representing a fundamental departure from conventional treatments focused primarily on symptom management. This review explores the evolving landscape of stem cell-based therapies for HF management. It delves into the mechanisms of action, clinical evidence from both positive and negative outcomes, ethical considerations, and regulatory challenges. Key findings include the potential for improved cardiac function, enhanced quality of life, and long-term benefits associated with stem cell therapies. However, adverse events and patient vulnerabilities necessitate stringent safety assessments. Future directions in stem cell-based HF therapies include enhancing efficacy and safety through optimized stem cell types, delivery techniques, dosing strategies, and long-term safety assessments. Personalized medicine, combining therapies, addressing ethical and regulatory challenges, and expanding access while reducing costs are crucial aspects of the evolving landscape.

Indexed as

Heart FailureStem Cell TransplantationHumansQuality of LifeCardiovascular diseaseClinical trialsHeart failureRegenerative medicineStem cell therapy

Identifiers

PMID37733137
OpenAlexW4386910074

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.